Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era

ConclusionWhile the real-world overall survival in Japanese patients with mRCC in the targeted therapy era improved compared to that previously reported in the cytokine era, there was no clear difference in the survival of poor risk patients between these eras. There were no differences in the superiority among the models.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research